α-半乳糖苷酶

α-半乳糖苷酶用途

α-半乳糖苷酶(EC 3.2.1.22),即α-半乳糖糖苷酶,是一种广泛存在于动物、植物和微生物中的糖苷水解酶,常用于生化研究。α-半乳糖苷酶催化α-1,6-连接的末端半乳糖残基的水解,包括低聚半乳糖、半乳甘露聚糖和半乳糖脂质。催化许多分解代谢过程,包括糖蛋白、糖脂和多糖的裂解[1]。

α-半乳糖苷酶名称

[ CAS 号 ]:
9025-35-8

[ 中文名 ]:
α-半乳糖苷酶

[ 英文名 ]:
α-galactosidase

[中文别名 ]:

[英文别名 ]:

Agalsidase
E.C. 3.2.1.22
alpha-Galactoside galactohydrolase
Melibiase
2-Quinoxalinecarbonyl chloride
quinoxaline-2-carbonyl chloride
alpha-D-Galactosidase
alpha-GAL 600L
alpha-D-Galactopyranosidase
Alpha-Gal 1000

α-半乳糖苷酶生物活性

[ 描述 ]:

[ 相关类别 ]:

研究领域 >> 其他

[参考文献]

[1]. Sonu Bhatia, et al. Microbial production and biotechnological applications of α-galactosidase. Int J Biol Macromol. 2020 May 1;150:1294-1313.

α-半乳糖苷酶物理化学性质

[ 密度 ]:
1.4±0.1 g/cm3

[ 沸点 ]:
324.4±22.0 °C at 760 mmHg

[ 分子式 ]:
C₉H₅ClN₂O

[ 分子量 ]:
192.602

[ 闪点 ]:
150.0±22.3 °C

[ 精确质量 ]:
192.009033

[ LogP ]:
2.12

[ 外观性状 ]:
buffered aqueous solution

[ 蒸汽压 ]:
0.0±0.7 mmHg at 25°C

[ 折射率 ]:
1.663

[ 储存条件 ]:
2-8°C

α-半乳糖苷酶安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P261-P305 + P351 + P338

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
36/37/38

[ 安全声明 (欧洲) ]:
36/37-26

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

α-半乳糖苷酶文献

High throughput screening for inhibitors of alpha-galactosidase.

Curr. Chem. Genomics 4 , 67-73, (2011)

Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency in α-galactosidase A (GLA), which catalyzes the hydrolysis of terminal α-galactosyl groups from glycosphingolipids, s...

Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.

Am. J. Physiol. Gastrointest. Liver Physiol. 306(2) , G140-6, (2014)

A defect in the gene for the lysosomal enzyme α-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular...

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.

PLoS ONE 7(10) , e47805, (2012)

Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotr...

更多文献